C-IU8NShift Bioscience
cell rejuvenation, aging clocks, siRNA therapeutics
reprogrammingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IU8N
C-IU8NC-IU8Ncell rejuvenation, aging clocks, siRNA therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The AI arms race just triggered its next explosive super-cycle, and if you are only watching Nvidia or Micron, you are missing the biggest paradigm shift of the decade. Washington just officially weaponized the CHIPS and Science Act, injecting $2.013 billion in federal funding across nine companies to aggressively build an untouchable domestic quantum computing supply chain. This isn't a long-term research project anymore; it is an active geopolitical sprint. The epicenter of this seismic shift is IBM, a legacy sleeping giant that just completely woke up. Big Blue secured a massive $1 billion federal match to launch "Anderon," America’s very first pure-play 300mm quantum chip foundry. Wall Street responded with absolute euphoria: IBM shares instantly surged over 12%, reversing its entire year-to-date slump in a single session. According to Wedbush’s tech titan Dan Ives, quantum computing isn't going to cannibalize AI—it is the ultimate "derivative play" and a compounding multiplier. Wh
Dan Ives, Managing Director and Senior Equity Research Analyst at Wedbush Securities, offers a clear-eyed perspective on the current state of the artificial intelligence market. By comparing the current investment landscape to a baseball game, Ives suggests we are merely in the third inning, hinting that significant opportunities remain. While the buzz around AI stocks is undeniable, the analysis pivots toward software as a major, potentially undervalued derivative trade. This breakdown moves beyond the hype of the 'Meg Seven' to examine where new money is flowing, the risks inherent in the trade, and the macro factors that could shift the market's trajectory. #WallStreet #Stocks #Investing #Investing #ArtificialIntelligence #StockMarket #TechStocks #Finance #DanIves #MarketAnalysis
Dan Ives, Managing Director and Senior Equity Research Analyst at Wedbush Securities, offers a sharp analysis of the current technology landscape. He explores why we are still in the early innings of the artificial intelligence boom and identifies the potential for a massive shift in market momentum. While everyone is focused on the usual tech giants, Ives shines a spotlight on under-the-radar opportunities, specifically calling out Pegasystems as a mid-cap play worth watching. The discussion digs deep into the risks facing the AI trade, the macroeconomic factors like oil prices that could disrupt current trends, and where savvy investors are placing their capital for the next wave of growth. #WallStreet #Stocks #Investing #AI #stocks #Investing #tips #Stock #market #analysis #Tech #stocks #Financial #news #Pegasystems #Artificial #intelligence
Dan Ives of Wedbush Securities provides a compelling timeline for when investors might see a potential turnaround for Tesla. By looking toward the summer and fall, he anticipates a pivotal shift driven by the scaling of robo-taxi technology. Furthermore, he offers an intriguing perspective on how a potential SpaceX IPO could ultimately serve as a significant catalyst for Tesla's long-term performance. This analysis cuts through the market noise to focus on the specific drivers set to define the next chapter for major tech holdings. #Stocks #Investing #WallStreet #Tesla #TSLA #Investing #StockMarket #DanIves #RoboTaxi #TechStocks #SpaceX #FinancialAnalysis
Live from the Milken Institute Global Conference 2026 on May 4, 2026, CEO David A. Steinberg and tech analyst Dan Ives discuss industry trends, Zeta’s recent earnings report, and Athena by Zeta’s early success. 00:00 Validation in the AI revolution 4:38 Why the software phase is just beginning 11:47 The global chip demand and the next market shift 14:36 The biggest opportunity in tech right now 19:45 What does AI really mean for jobs? 24:11 How Athena turned Zeta into an innovation engine Note: This video includes highlights from the discussion and has been edited for clarity. Disclosure from Wedbush: The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an off
The mainstream financial media is currently obsessed with short-term market volatility and geopolitical noise, but the smartest money on Wall Street is looking at a singular, undeniable data point: the $1 trillion global AI infrastructure build-out. Wedbush’s Dan Ives just dropped a massive bombshell for tech investors, declaring that we are only in the "third inning" of a nine-inning global AI game. Despite the headlines, Ives is projecting at least a 15% upside remaining for the tech sector this year alone. This isn't just blind optimism; it is a thesis backed by a staggering 12-to-1 demand-to-supply ratio for high-end AI chips and a projected tidal wave of capital expenditure that is rewriting the rules of corporate valuation. We are moving past the era of pure speculation and into the era of "AI or Die" monetization. We are currently witnessing a fundamental shift where every $1 invested in AI hardware is triggering a massive $8 to $10 multiplier effect across the broader software
What if an AI could run centuries of aging experiments in a single year, and pinpoint one gene that matches the rejuvenating power of Yamanaka factors — but without the cancer risk? Dr. Daniel Ives, CEO of Shift Bioscience (Cambridge), explains how his team used a virtual cell to discover SB000: a single gene capable of multi-tissue cellular rejuvenation. https://youtu.be/jVQ4kl5YFls
Dr. Daniel Ives is the founder of Shift Bioscience. Shift has built a novel single-cell aging clock that has enabled them to run high-throughput screens to discover genes that regulate aging, with the goal of identifying a therapy to systemically reverse aging. We’ll dive deep into Shift’s latest work on SB000, a germline-expressed gene that rejuvenates cells without inducing pluripotency, and SB101, a pro-aging gene whose inhibition both reverses cellular age and prevents fibrosis, opening a clear path to clinical development. Daniel also shares his philosophy on why reversing aging might be easier than we think, the coming cultural shift when anti-aging drugs become mundane reality, and why he won’t rest until we can double human lifespan. 0:00 Intro 1:37 Deciding to work on aging 5:52 Origins of Shift Bioscience 9:54 Role of mitochondria in aging 13:03 Aging clocks & the meeting that led to XPRIZE Healthspan 18:11 Cracking the single cell aging clock 21:45 The accuracy and role o
What if an AI could run centuries of aging experiments in a single year, and pinpoint one gene that matches the rejuvenating power of Yamanaka factors — but without the cancer risk? Dr. Daniel Ives, CEO of Shift Bioscience (Cambridge), explains how his team used a virtual cell to discover SB000: a single gene capable of multi-tissue cellular rejuvenation. CHAPTERS: 00:00 — Centuries of experiments in a year: the AI advantage 02:03 — Daniel's journey: physics → Aubrey de Grey → longevity biotech 04:06 — Pivoting Shift Bioscience to machine learning 06:06 — How AI and Aubrey de Grey shaped the field 08:07 — The problem with hypothesis-driven research in aging 10:08 — The epigenetic clock: the breakthrough that changed everything 12:09 — The 13 mitochondrial genes and why they matter 14:09 — Why the epigenetic clock is the field's key measuring tool 16:09 — Energy metabolism, epigenetic drift, and aging 18:09 — Mutations vs. epigenetics: what actually drives aging 20:09 — Yamanaka factor
Dan Ives, Global Head: Technology at Wedbush Securities, discusses Oracle's share surge after the company's strong outlook for its cloud business. Oracle Corp. shares gained the most since 1992 after the company gave an aggressive outlook for its cloud business, cementing the software maker’s place in the race to support demand for artificial intelligence computing. The stock surged as much as 41% Wednesday morning in New York, bringing its market valuation to $947 billion and co-founder Larry Ellison to within striking distance of Elon Musk as the world’s richest person. AI-related stocks such as chip developer Nvidia Corp. and Asian suppliers also climbed. Known for its database software, Oracle has recently found success in the red-hot cloud computing market and is emerging as a key provider of AI computing capacity, competing against cloud leaders Amazon.com Inc., Microsoft Corp. and Alphabet Inc.’s Google. Earlier this summer, it signed an unprecedented deal with ChatGPT operato
Just about the hottest thing in longevity science right now is partial reprogramming - using Yamanaka factors to rewind the biological clock in our cells. Billion-dollar giants like Altos, Retro and New Limit are betting on it. But in this episode a far smaller player, Shift Bioscience, argues that the field may be looking in the wrong place. CEO Daniel Ives explains how his team used AI-powered virtual cells to uncover a single gene that seems to match OSK-level rejuvenation without the tumor risk that haunts classical reprogramming - and why their just-released data could change the game for aging research. 🔍 In this conversation ✅ Daniel’s journey from mitochondrial PhD work to founding Shift Bioscience. ✅ Why Yamanaka-factor–based partial reprogramming excites the field and why it’s inherently risky. ✅ Epigenetic clocks 101 — Horvath, single-cell versions, and what they really measure. ✅ Building AI “virtual cells” (transformers / GNNs) to run millions of in-silico experiments. ✅
Held online on 14 November 2024, Investing in the Age of Longevity 2024 offered an unparalleled opportunity for investors to help build their longevity investment portfolios. Exploring "Longevity Next" and "Longevity Now", the masterclass once again attracted scientists and business leaders from the cutting edge of the field, giving participants a run-down of the latest sector developments and investment opportunities. Key moments: 00:00 Intro 00:10 Phil Newman – Longevity.Technology Phil Newman, Founder and CEO at Longevity.Technology, delivers the opening remarks at Investing in the Age of Longevity 2024. Introducing the format of the event, which includes a review of "Longevity Next" and "Longevity Now", Phil gives an overview of the longevity market, including the sector's past and current financing environment. He also shares Longevity.Technology's new 10-level classification for analysing the industry, and outlines the trends and investment opportunities that each level en
Daniel Ives, CEO at Shift Bioscience, presents at Investing in the Age of Longevity 2024. In his talk, Daniel demonstrates the risk posed by genes that can reverse age and rescue disease. Showcasing the significant increase in experimental power offered by AI cell simulations, he explains how Shift Bioscience uses this type of approach as a path toward safer and simpler cell rejuvenation and disease rescue. Find out more about past and upcoming Master Investor webinars: https://events.masterinvestor.co.uk Keep in touch: Substack | https://masterinvestoruk.substack.com Newsletter | https://masterinvestor.co.uk/subscribe Twitter | https://twitter.com/masterinvestor Facebook | https://facebook.com/masterinvestor LinkedIn | https://linkedin.com/company/masterinvestor TikTok | https://www.tiktok.com/@masterinvestoruk
Daniel Ives, Managing Director of Equity Research at Wedbush Securities, anticipates strong SAP growth in AI as 45% of workloads shift to the cloud, viewing SAP's earnings as a key indicator for Amazon and Google amid rising enterprise spending on AI.
In the wide and complex subject of biological aging, one particular kind of biological aging has been receiving a great deal of attention in recent years. That’s the field of epigenetic aging, where parts of the packaging or covering, as we might call it, of the DNA in all of our cells, alters over time, changing which genes are turned on and turned off, with increasingly damaging consequences. What’s made this field take off is the discovery that this epigenetic aging can be reversed, via an increasing number of techniques. Moreover, there is some evidence that this reversal gives a new lease of life to the organism. To discuss this topic and the opportunities arising, our guest in this episode is Daniel Ives, the CEO of Shift Bioscience. As you’ll hear, Shift Bioscience is a company that is carrying out some very promising research into this field of epigenetic aging. Daniel has a PhD from the University of Cambridge, and co-founded Shift Bioscience in 2017. The conversation high
Shift Bioscience is using deep learning to unlock cellular reprogramming, a powerful biological pathway that can reverse aging and age-driven diseases in the dish but is not yet safe for clinical use. Dr. Daniel Ives, Shift Bioscience With this lecture I would like to describe two journeys, the science journey and the personal journey of the science. The journey of the science starts with hypothesis driven investigation, through crude computational biology, to the first applications of machine learning, to the construction of massive datasets ending with effective cell simulations. The personal journey of the science starts with a singular TED talk by an eccentric Cambridge geneticist, progressing to academia, embracing poor odds, personally funding science, building a team, learning to communicate properly and building the company to make it all real. I received my PhD from the University of Cambridge where I focused on the role of mutations in the mitochondrial genome in rare dise
Dr Brendan Swain Chief Scientific Officer, Shift Bioscience 21 November, 2023 In collaboration with the Cambridge Society of Ageing and Longevity Research - About the Cambridge University Scientific Society: We are the the University of Cambridge's foremost and most active science society, and the home of science at Cambridge. Our mission is to promote all branches of science and to make science accessible to all members of the University and the wider general public. Sign up for our mailing list to receive email updates about our latest talks and events: http://bit.ly/scisocmembership Website: https://scisoc.com Facebook: Cambridge University Scientific Society Instagram: @cambridgescisoc Twitter: @CambridgeSciSoc Email: [email protected]
Moderator: Adrian Toutoungi, Taylor Wessing Panellists: Janette Thomas, Five Alarm Bio Ltd, Panteli Theocharous, PPD, Daniel Ives, Shift Bioscience, Delphine Larrieu, University of Cambridge, Rebecca Canter, Eli Lilly
Jellyfish filmmakers chat with Daniel Ives of Shift Bioscience about the power of movies and media to impact public perception on longevity. In collaboration with VitaDAO.
Today I am on the road and have come to visit Daniel Ives, CEO of Shift Bioscience in Cambridge, UK. Shift Bioscience are a longevity biotech company using machine learning to develop therapeutics for safe cellular reprogramming - the resetting of cells and tissues to a youthful state. After a quick tour inside the building, I sat down with Daniel to discuss his contributions to the longevity field, his vision and approach for Shift Bioscience and what it's like to run a company. Find Daniel on Twitter - https://twitter.com/dives86 Shift Bioscience - https://www.shiftbioscience.com/ Find me on Twitter - https://twitter.com/EleanorSheekey https://www.thesheekeyscienceshow.com/ Support the channel through PayPal - https://paypal.me/sheekeyscience?country.x=GB&locale.x=en_GB through Patreon - https://www.patreon.com/TheSheekeyScienceShow TIMESTAMPS: Inside Shift Bioscience - 00:00 Interview with Daniel - 01:25 PhD work and mitochondria - 02:00 Mitochondrial theory of aging & 2-
At Shift Bioscience, Dr. Daniel Ives is making drugs for safer cellular rejuvenation in humans through the application of machine-learning 'driver' clocks to cellular reprogramming. Daniel is also a founding fellow of the OnDeck Longevity Biotech fellowship, a continuous community for people to come together to build, join, or invest in revolutionary longevity biotechnology startups. FOLLOW US ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ https://www.lifespan.io https://www.facebook.com/lifespanio https://www.instagram.com/lifespan.io/ DESCRIPTION ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ As a University of Cambridge PhD student, Daniel joined Ian Holt's group at the Mitochondrial Biology Unit to pursue damage-removal strategies for mitochondrial DNA mutations, which cause rare mitochondrial disease and are sufficient to accelerate aging phenotypes in mouse models. Harnessing publicly available transcriptome data from the NCBI GEO database, Daniel used a computationally guided screen to identify small-molecule tool
Our future is not a given, not something to be predicted. Our future is a decision, something to be imagined. Following this philosophy, we have been working on bringing you something new: the Foresight LAB GALLERY [opensea.io/LabGallery], a digital art gallery where artists and scientists join forces to share visions of better futures catalyzed by breakthrough innovations. LAB GALLERY is the first purpose driven digital art gallery – merging art and science to accelerate progress in transformative tech for the long-term flourishing of life. LAB GALLERY creates NFT collections where artists transpose scientists’ cutting-edge research into visions of the future– offering collectors the opportunity to fund revolutionary science while collecting art. Check out the gallery to learn about our featured scientists’ inspiring research, and allow a different part of your mind to be stirred by our artists’ visionary aesthetic inputs. About the first collection: In CREATIVE NATURE OF TOTAL S
Talk Title: A path to safe cellular rejuvenation Daniel Ives, CEO and Founder of Shift Bioscience, presents at Investing in the Age of Longevity 2021. In his talk, Daniel stresses the importance of safe cell reprogramming for comprehensive rejuvenation. Daniel also describes how Shift Bioscience applies machine learning to help tame cell reprogramming and safely reset cells and tissues, thus mitigating the diseases of aging. Download the presentation slides: https://bit.ly/3HYSNKS Investing in the Age of Longevity 2021 was held in London on 17 November 2021. The one-day masterclass brought together scientists and business leaders at the cutting edge of the field, who shared the inside track on the latest aging-related discoveries and investment opportunities. Download the event programme: https://bit.ly/3lc0Z0j Find out more about Master Investor: https://www.masterinvestor.co.uk
A Metabesity conference session answering the questions: What is needed to put biomarkers to work in therapeutic development, regulated product approval, and clinical management? How can we find reliable biomarkers of aging that predict and demonstrate effective interventions? What does/should a biological clock measure? Moderator: Morgan Levine, PhD, Assistant Professor of Pathology and Epidemiology at Yale School of Medicine Dan Belsky, PhD, Assistant Professor of Epidemiology at the Robert N. Butler Columbia Aging Center, Mailman School of Public Health, Columbia University Bobby Brooke, MSc, CEO of Intervene Immune, Inc. and Executive Director of The Clock Foundation Daniel Ives, PhD, CEO of Shift Bioscience, UK Miсhelle Keller, Senior Manager of Scientific Business Development at Deep Longevity, Russia Jamie Justice, PhD, Assistant Professor at Wake Forest University School of Medicine Chris Leptak, MD, PhD, Senior Vice President, Drug and Biological Products at Greenleaf Healt
A Metabesity 2021 Emerging Company Showcase presentation on Shift Bioscience by Daniel Ives, PhD, CEO. Cell reprogramming offers a path to comprehensive rejuvenation, but has a goldilocks problem. Too little and you have no rejuvenation, too much and you risk cancer. To fulfill its potential, cell-reprogramming must be made safe. Based on a novel application of machine learning, Shift Bioscience has identified an opportunity to tame cell reprogramming and safely reset cells and tissues back to a youthful state.
Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning 'driver' clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based. Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute, pursuing damage-removal strategies for mitochondrial DNA mutations. In 2016 Dr. Ives left the Crick Institute and founded Shift Bioscience to commercialize mitochondrial targeted drugs for age linked diseases, incorporating novel ageing biomarkers technologies, CRISPR screens, and other tools to dissect
Seminar summary: https://foresight.org/summary/drug-target-discovery-for-cellular-rejuvenation-by-driver-clocks-daniel-ives-shift-bioscience/ Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital 2021 program & apply to join: https://foresight.org/biotech-health-extension-program/ Daniel Ives, Shift Bioscience, Shift Bioscience Drug target discovery for cellular rejuvenation by the application of ‘driver’ clocks to cell reprogramming At Shift Bioscience Daniel is making drugs for cellular rejuvenation in humans through the application of machine-learning 'driver' clocks to cellular reprogramming. Daniel was inspired to pursue a Longevity mission in 2009 after reading Aubrey de Grey’s 2007 book ‘Ending Aging’. As a U. Cambridge PhD student, Daniel joined Ian Holts group at the Mitochondrial Biology Unit to pursue damage-removal strategies for mitochondrial DNA mutations, which cause rare mitochondrial disease and are sufficient to accelerate ageing phenotypes in
Daniel Ives: Bootstrapping Longevity Biotech Thu Apr 1, 2021 4:00-7:00pm EDT Daniel Ives is founder and CEO of Shift Bioscience (shiftbioscience.com). Based in the UK, Shift Bioscience develops small molecules with the potential to reverse aging and increase healthy lifespan. Biotech startups like Shift are expensive, but it *is* possible to start on a small budget. Daniel bootstrapped his company before getting to investability and shared a bit of the story of how he did it.
Shift Bioscience Ltd introduce themselves as part of the cofinitive #21toWatch longlist for 2019/20
SEI Torino Forum 2018 - June 7th Inspiring the next generation of entrepreneurial leaders in Europe
The suppression of free speech on college campuses isn’t a new thing, says Jon Haidt, social psychologist at New York University Stern School of Business. In the past, however, it seems to have been guided mostly by the professoriate and administrations rather than the students. _______ Subscribe to our YouTube channel: http://youtube.com/reasontv Like us on Facebook: https://www.facebook.com/Reason.Magazine/ Follow us on Twitter: https://twitter.com/reason Subscribe to our podcast at iTunes: https://goo.gl/az3a7a _______ Haidt says student-driven speech suppression is a relatively new phenomenon. “It was after the Yale protests that everything really spread,” Haidt says, “and that was only thirteen or fourteen months ago.” According to Haidt, one of the root causes of the shift toward a leftist academia was the Baby Boomers who rushed to avoid the Vietnam war. However, the ideas behind PC and microaggressions didn’t catch on for several decades. “The thing people were not expect
Dr. Daniel Ives, Ph.D. - Founder and CEO - Shift Bioscience Ltd. - Driver Clocks And Longevity | Progress, Potential, and Possibilities Podcast / Show Episodio en Amazon Music Inicio Inicio Podcasts Podcasts Biblioteca Cancelar Iniciar sesión Dr. Daniel Ives, Ph.D. - Founder and CEO - Shift Bioscience Ltd. - Driver Clocks And Longevity Progress, Potential, and Possibilities Podcast / Show 13-08-2021 • 56 minutos Send us Fan Mail Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. ( https://shiftbioscience.com ), a biotech company making drugs for cellular rejuvenation in humans … a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning 'driver' clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based. Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral st
Shift Bioscience on Free Radicals Podcast | Milner Therapeutics Institute posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
#112, Defeating the Diseases o… - AWS Health Innovation Podcast - Apple Podcasts Search Home New Top Charts Search December 18, 2024 32 min #112, Defeating the Diseases of Aging with Daniel Ives from Shift Bioscience AWS Health Innovation Podcast Play Imagine being able to reverse the biological clock and restore youth. That's the ambitious goal of Shift Bioscience, a biotech company pioneering novel gene-based cell rejuvenation therapies. In this episode of the AWS Health Innovation Podcast, Sanjit Misra from AWS hosts an in-depth conversation with Daniel Ives, the CEO and Founder of Shift Bi
Finding genes at scale for age reversal - Shift Bio CEO Daniel Ives - Free Radicals | Podcast on Spotify
Dr Daniel Ives on Shift Bioscience's Anti-Aging Breakthrough | Eric Dai posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … emically reverse aging. They’ve raised $16M from investors like Business Growth Fund, F-Prime , and Kindred Capital VC to pursue this mission. In this episode, we discuss Shift’s formation and their approach, and dive deep into two promising targets they’ve discovered, as well as the coming cultural shift when anti-aging drugs become mundane reality. Check out the trailer below, and follow the links to see the full episode. YouTube: https://lnkd.in/e_dUiARM Spotify: https://l
--> Rejuvenation Resources Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal An
Instagram Instagram Log In Sign Up Close Never miss a post from ageingandlongevity Sign up for Instagram to stay in the loop. Sign up Log in ageingandlongevity • Follow More options ageingandlongevity 81w 🧬 Curious about the future of longevity? Brendan Swain, CSO and Co-Founder of Shift Bioscience, is leading research that targets cellular aging through safe reprogramming, aiming to restore youthful cellular function and delay age-related decline. Join us on November 14th, 2024 - RSVP in bio! Load more comments No comments yet. Start the conversation. Like 13 Comment Share Save November 8, 2
Shift Bioscience's epigenetic rejuvenation update at London Longevity Network | London Longevity posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu … post Angela Goncalves — Science Breakthrough of the year in the Women’s Impact Award category — is breaking the wall of healthy aging in women by mapping the female reproductive tract across the lifespan. Using AI, single-cell genomics, and non-invasive menstrual fluid sampling, her research reveals how reproductive cycles influence healthy ageing and the early onset of diseases such as endometriosis and ovarian cancer. By combining molecular biology with clinical insight, Â … iving everyday people students, builders, dreamers, and believers, the power to fund discovery, to own innovation, and to push humanity forward. Then came Arthur Hayes, with a tone that blended discipline and experience. He spoke not just as an investor or thinker, but as an athlete someone who has learned to respect time, patience, and health. He said he wants to do what he loves, live freely, and embrace a healthier life. He believes in stem cell treatments not because they … ch Priorities 🧠 Excited to see the 10 semifinalist teams of the AlzInsights AI Prize advancing dementia research in ways that directly support WHO’s Blueprint for dementia research. These projects tackle key gaps across the Blueprint’s six thematic areas, strategic goals and milestones. From digital twins and virtual cell models to multimodal data harmonization and synthetic data generation, these teams are accelerating progress toward more inclusive, data-driven, and impact … selected to advance to the next round of the $1 Million Alzheimer's Insights AI Prize! These projects demonstrated strong scientific and technical merit, innovative application of agentic AI, and clear potential to contribute to Alzheimer's and related dementias research. We're excited to see their pitches and witness how these teams are driving
Instagram Instagram Log In Sign Up Close Never miss a post from culongevity Sign up for Instagram to stay in the loop. Sign up Log in culongevity • Follow More options culongevity Edited • 132w 🎉 We are delighted to host Brendan Swain - Chief Scientific Officer and co-founder of Shift Bioscience 📅 on Tuesday 21st of November 17:30 GMT at the Bristol-Myers Squibb Lecture Theatre in the Dept of Chemistry, together with @cambridgescisoc on: Unlocking Safe Reprogramming with Deep Learning 💻 🧬🔬 ! This will be followed by drinks and networking at The Prince Regent 🍺 See you there! 🔥 #longevit
Shift Bioscience identifies safer anti-ageing gene target | Babraham Research Campus posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … a target for safer, next-generation cell rejuvenation therapeutics, with broad application across age-driven diseases. Shift will now proceed with further studies to progress SB000 as a therapeutic target, including research to confirm efficacy across an even broader range of disease-relevant cell types, and to advance to in vivo proof-of-concept rejuvenation studies. Full story 👇 https://ow.ly/Y3kA50W7JPh Shift Bioscience identifies novel single-gene target for safer cellu … Mary Brunkow and Fred Ramsdell, and Japan's Shimon Sakaguchi—won the 2025 Nobel Prize in Medicine for their discoveries in peripheral immune tolerance which could lead to new treatments for autoimmune diseases and cancer. The discovery of the FOXP3 gene, which controls the development of regulatory T cells, was highlighted as a significant contribution by Ramsdell and his colleagues, with over 200 human trials involving these cells currently in progress. Companies like Sonoma
All Shift Bioscience articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars Whitepapers Reports H
--> GtR Home About this system Release history Contact us 📣 Help Shape the Future of UKRI's Gateway to Research (GtR) We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email [email protected] . Search All Data Advanced Advanced --> Please select the required search fields: ORCID iD --> Project Abstract Project Reference --> Project Title --> Projects … ve qPCR profiling test for improved, personalised patient pathways. Innovate UK award to SIGNATUR BIOSCIENCES LTD and Celestin De Wergifosse £249,760 Mar 23 - Jun 25 Innovative automation to find new interventions that slow ageing Innovate UK award to MAGNITUDE BIOSCIENCES LIMITED and Matthew Bell £218,800 Sep 17 - Mar 18 AMLo Biosciences Limited Innovate UK award to AMLO BIOSCIENCES LIMITED and Ashleigh McConnell £7 … stock derived from non-food waste - Pulpex UK BioScience Initiative Innovate UK award to PULPEX LIMITED and Scott Winston £349,062 Apr 21 - Nov 22 Development of rice blast resistance using Genome Editing induced Gene Silencing (GEiGS) Innovate UK award to TROPIC BIOSCIENCES UK LIMITED and Fabricio Minatel £139,259 Jan 17 - Mar 18 Generation of Small Molecule Asthma Disease Modifying Agents from a TB Derived Peptide Lead Innovate UK awa … eloping a Novel, Precise and Programmable Genome Editing Technology Innovate UK award to PENCIL BIOSCIENCES LIMITED and Rajik Ibrahim £349,993 Jun 23 - Dec 24 Discovery of safe and effective gene targets for cellular reprogramming therapies Innovate UK award to SHIFT BIOSCIENCE LIMITED and Brendan Swain £206,180 Apr 25 - Apr 26 Acceleration of Drug Discovery through the development of High-Throughput Screening with Advanced Robotics and … gh-Throughput Screening with Advanced Robotics and Machine Learning Innovate UK award to MAGNITUDE BIOSCIENCES LIMITED and Sara Leighton £103,686 Dec 17 - Aug 18 Inactivation of Antibiotic Resistance in Clinical Isolates of Pathogenic Enterobacteriaceae Innovate UK award to NEMESIS BIOSCIENCE LTD £186,080 Mar 19 -
AI Summit - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs In … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Companies Participati … g™ Spotlights Amgen Genentech Boehringer Ingelheim Lilly Sanofi Academic Campus Apply for Academic Campus Exhibition Exhibition Directory Exhibitor List Exhibition Map Networking Networking at BIO Receptions Exhibitor In-Booth Events Other Events Social Spotlight Events Affiliate Events Application List your event Special Experiences 5K and 1 Mile Course Match Day Lounge Travel Hotel Reservations Book Your Hotel Interactive Hotel Map Hotels by Amenity Hotel Guidelines Transpo … , high-fidelity genomic data, represents a major shift in how we understand and apply biology. Large-scale AI models trained on genomic and transcriptomic data enable researchers to predict biological behavior before running an experiment - accelerating discovery, improving clinical decision-making, and enabling more efficient d ... 3:00 PM – 4:00 PM AI Summit Session AI and Digital Health 28ABCDE Twitter LinkedIn Email Share Data Hunger, Enterprise Risks: Biomedical Data and
Shift Bioscience - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Companies Participati … g™ Spotlights Amgen Genentech Boehringer Ingelheim Lilly Sanofi Academic Campus Apply for Academic Campus Exhibition Exhibition Directory Exhibitor List Exhibition Map Networking Networking at BIO Receptions Exhibitor In-Booth Events Other Events Social Spotlight Events Affiliate Events Application List your event Special Experiences 5K and 1 Mile Course Match Day Lounge Travel Hotel Reservations Book Your Hotel Interactive Hotel Map Hotels by Amenity Hotel Guidelines Transpo
dsm-firmenich - We’re ready to challenge the way the... Facebook Вход Публикация dsm-firmenich dsm-firmenich 12 май в 06:05 · Поделился/-ась с Доступно всем We’re ready to challenge the way the industry thinks about health longevity. Last week, we brought our #LongevityShift experience to VitaFoods Europe 2026. For too long, the conversation has been about adding years to life. We're here to shift that focus to adding health to years. That’s what health expectancy is about – targeting the cellular hallmarks of aging through science-backed solutions. We highlighted two specific innovations
Shift Bioscience Establishes North American Facilities to Expand Capabilities of AI-Powered Virtual Cell Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Shift Bioscience Establishes North American Facilities to Expand Capabilities of AI-Powered Virtual Cell Technology February 18, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Head of Machine Learning, Lucas Camillo, to lead team with Professor Bo Wang, University of Toronto, appointed as Senior … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics Pipeline - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics Pipeline March 12, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Shift Bioscience Appoints Lord David Prior and Sir Tony Kouzarides to Support Long-Term Strategy for Cell Rejuvenation Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Dea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Shift Bioscience Appoints Lord David Prior and Sir Tony Kouzarides to Support Long-Term Strategy for Cell Rejuvenation Therapeutics May 20, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
The first human test of a rejuvenation method will begin “shortly” | MIT Technology Review You need to enable JavaScript to view this site. Skip to Content MIT Technology Review Featured Topics Newsletters Events Audio MIT Technology Review Featured Topics Newsletters Events Audio Biotechnology and health The first human test of a rejuvenation method will begin “shortly” In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers. By Antonio Regalado archive page January 27, 2026 Harvard University researcher David Sinclair says aging can b … g that rejuvenates … So watch this space.” The technology is based on the Nobel Prize–winning discovery, 20 years ago, that introducing a few potent genes into a cell will cause it to turn back into a stem cell, just like those found in an early embryo that develop into the different specialized cell types. These genes, known as Yamanaka factors, have been likened to a “factory reset” button for cells. But they’re dangerous, too. When turned on in a living animal, they can ca
Shift Bioscience Raises $16M to Advance Cell Simulation AI Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Shift Bioscience Raises $16M to Advance Cell Simulation AI Platform October 15, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Investment led by BGF, with support from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner Seed funding will accelerate development of Shift Biosci … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Shift Bioscience Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 17 Feb 2026 Shift Bioscience Ltd. Startups | Holding Company | 2017 | United Kingdom | 10-50 | www.shiftbioscience.com Startups | Holding Company | 2017 | United Kingdom | 10-50 | www.shiftbioscience.com Last update 17 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Digestive System Disorders Small molecule drug AAV based gene therapy siRNA … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics - The Milner Therapeutics Institute HOME ABOUT US Mission & Values Our Team Our Facilities Milner Boards Careers & Opportunities RESEARCH Target Discovery Functional Genomics Screening Laboratory AI and Computational Research PARTNERSHIPS Therapeutics Consortium Consortium Call Partnerships & Affiliates ENTERPRISE Bio-incubator Enterprise Initiatives NEWS Latest News Milner Newsletter EVENTS Events Calendar Annual Symposium Symposium Overview Symposium 2026 Symposium 2025 Milner Pit … a target for safer, next-generation cell rejuvenation therapeutics, with broad application across age-driven diseases. Existing approaches to cell rejuvenation primarily focus on the Yamanaka Factors (OSKM), a combination of genes that can be used to reverse cellular aging but are known to induce pluripotency that may result in tumorigenesis, limiting their use in a therapeutic setting. In this seminal study, SB000 demonstrated cellular rejuvenation at both methylome and tra
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatolo … a target for safer, next-generation cell rejuvenation therapeutics, with broad application across age-driven diseases. Existing approaches to cell rejuvenation primarily focus on the Yamanaka Factors (OSKM), a combination of genes that can be used to reverse cellular aging but are known to induce pluripotency that may result in tumorigenesis, limiting their use in a therapeutic setting. In this seminal study, SB000 demonstrated cellular rejuvenation at both methylome and tra … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × New genetic roadmap offers targeted treatment for rare inflammatory disorder
Home - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Cell rejuvenation to rewind age driven diseases. Uncovering the biology of cell rejuvenation to end morbidity and mortality from aging . Discover Introduction. At Shift, we’re targeting the underlying cause of age driven diseases, the aging cell. With age, health costs rise an order of magnitude, peaking at £10k/yr (UK, 2020-21) due to an increased prevalence of a
Dr Daniel Ives Health Horizons Speaker - Daniel Ives Home About Speakers Board Agenda Venues Getting here Acommodations Partners Contact Dr Daniel Ives Founder & CEO, Shift Bioscience About Daniel Ives is CEO and founder of Shift Bioscience, a preclinical drug discovery and development company developing the first small molecule drug for safe repair of mitochondria, the energy producing organelle. Daniel was a mitochondrial researcher for 7 years (2009-2016), based first at the MRC Mitochondrial Biology Unit and later at the Crick Institute. Daniel discovered small molecules that restore mitoc
CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Media CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight July 8, 2021 October 15th, 2025 Reversing Ageing with Daniel Ives of Shift Bioscience CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight. Listen to the content at BioInnovation Spotlight . Listen to Podcast
Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Media Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology December 17, 2024 October 5th, 2025 #112 Defeating the Diseases of Aging with Daniel Ives from Shift Bioscience Listen to Podcast About Shift Bioscience Sh
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin News Publications Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics June 9, 2025 October 8th, 2025 SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity … a target for safer, next-generation cell rejuvenation therapeutics, with broad application across age-driven diseases. Existing approaches to cell rejuvenation primarily focus on the Yamanaka Factors (OSKM), a combination of genes that can be used to reverse cellular aging but are known to induce pluripotency that may result in tumorigenesis, limiting their use in a therapeutic setting. In this seminal study, SB000 demonstrated cellular rejuvenation at both methylome and tra … in the body age – to reverse age and combat disease, we must design drugs that apply to all cell types ‘Cell aging clocks’ are used to accurately assess cell and tissue age DNA methylation clocks are accurate age predictors across tissues and cell types Blood-based aging clocks provide accurate predictions of mortality A pathway involving four genes, OSKM , has been shown to reverse aging in DNA methylation clocks across multiple cell types. Unfortunately, OSKM also induces
All Dr Daniel Ives (CEO of Shift Bioscience) articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webina
Daniel Ives - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Daniel Ives Ph.D CEO & Founder Leadership. Daniel founded Shift Bioscience in 2017 during postdoctoral research at The Francis Crick Institute. Since then, Daniel has led the Company through a sustained period of growth and discovery milestones, operating at the intersection of computational and cellular biology whilst shaping the Company’s vision to de
Brendan Swain - Chief Scientific Officer at Shift Bioscience | The Org Platform Enrich Pricing Log in Sign up Shift Bioscience Brendan Swain Unverified BS Brendan Swain Chief Scientific Officer Contact Brendan Swain, PhD, is currently serving as the Chief Scientific Officer at Shift Bioscience, a position held since March 2021. Prior to this role, Brendan completed a Doctor of Philosophy in Pharmacology at the University of Cambridge from 2016 to 2020, following an undergraduate degree in Natural Sciences with a focus on Pharmacology at the same institution from 2013 to 2016. Brendan's
US20240331801A1 - Temporal property predictor - Google Patents US20240331801A1 - Temporal property predictor - Google Patents Temporal property predictor Download PDF Info Publication number US20240331801A1 US20240331801A1 US18/579,196 US202218579196A US2024331801A1 US 20240331801 A1 US20240331801 A1 US 20240331801A1 US 202218579196 A US202218579196 A US 202218579196A US 2024331801 A1 US2024331801 A1 US 2024331801A1 Authority US United States Prior art keywords data set data samples embedded time Prior art date 2021-07-16 Legal status (The legal status is an assumption and is not a legal concl … s and makes no representation as to the accuracy of the status listed.) Pending Application number US18/579,196 Other languages English ( en ) Inventor Brendan SWAIN Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Shift Bioscience Ltd Original Assignee Shift Bioscience Ltd Priority date (The priority date is an assumption and is not a legal conclusion. … sted.) 2021-07-16 Filing date 2022-07-15 Publication date 2024-10-03 2022-07-15 Application filed by Shift Bioscience Ltd filed Critical Shift Bioscience Ltd 2024-01-30 Assigned to SHIFT BIOSCIENCE LTD. reassignment SHIFT BIOSCIENCE LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Swain, Brendan 2024-10-03 Publication of US20240331801A1 publication Critical patent/US20240331801A1/en Status Pending legal-status Critical Current Links USPTO USPTO Pat … ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS G16B — BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY G16B25/00 — ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression G16B25/10 — Gene or protein expression profiling; Expression-ratio estimation or n … ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS G16B — BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY G16B40/00 — ICT specially adapted for biostatistics; ICT speci
Shift Bioscience Ltd. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News T-Curx GmbH Acquires Pantherna Therapeutics GmbH Lilly: 3 Acquisitions to Build Infectious Disease Portfolio Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Qiagen Announces Collaboration with Nvidia at Bio-IT World Bilfinger: £15m Biopharma Maintenance Contract in Scotland Lauxera Capital Partners Closes Growth II Fund at €520m Hansa Biopharma: … rlet Therapeutics Closes £3.2m Seed Round Led by Eos » More News! » Submit your News! Upcoming Events Future Labs Live 2026 Basel LSN Health & Life Science Venture Day 2026 Hamburg William Blair & Company Annual Growth Stock Conference 2026 Chicago Jefferies 2026 Global Healthcare Conference New York SaxoCell Conference 2026 Dresden Festival of Genomics & Biodata 2026 Boston IHMC 2026 Seoul (International Human Microbiome Consortium Congress 2026) Knowledge for Gr … it 2026 Leipzig EUROMAR 2026 Gothenburg (Göteborg) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camila Japur Joins Tecan as CFO on 1 Jun 2026 Birgit Girshick Succ … c Appoints Ashiq H. Khan as Chief Commercial Officer » More News! » Submit your News! Financings & Acquisitions InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange Roche to Acquire PathAI for up to $1.05b Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1b Scarlet Therapeutics Closes £3.2m Seed Round Led by Eos CellCentric Announces $220m Serie … Has Acquired the IMIDomics’ Patient Insight Business » More News! » Submit your News! Collaborations & Licensing Hansa Biopharma: €115m Licensing Agreement with SERB GSK Licenses siRNA Oligo Drug from SiranBio for up to $1b Biesterfeld & Traceless Materials Form Strategic Partnership Medistrava Is Media Contact for Cytospire Therapeut
Shift Bioscience-VCBeat VCBeat Health Contact Us Home China Healthcare Select Insights MNC China Lens Vertical Industries Services Partnership Development Market Entry Advisory Ecosystem Engagement Advisory About VCBeat Why VCBeat Log In Home Shift Bioscience Shift Bioscience In operation Seed Round Financing Developer of Biological Aging Technologies Basic Information Shift Bioscience is a company that uses artificial intelligence to develop aging clocks and utilizes these clocks to explore methods capable of safely resetting cells and tissues to achieve the reversal of aging. The compa
Shift Bioscience raises $16M to advance AI virtual cell platform for cell rejuvenation - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin News Shift Bioscience raises $16M to advance AI virtual cell platform for cell rejuvenation October 15, 2024 October 5th, 2025 Investment led by BGF, with support from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner Seed funding will accelerate development of
Company - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Cell rejuvenation to rewind age driven diseases. Discover Overview. At Shift Bioscience, our mission is to increase both healthspan and lifespan. Shift’s leading target ID platform has identified an anti-fibrotic siRNA therapeutic for cell rejuvenation, providing a straightforward regulatory path to clinical proof of concept, with first in class opportunities i
Brendan Swain | OpenReview OpenReview .net OpenReview .net Login OpenReview .net Login Brendan M. Swain Principal Researcher, Shift Bioscience Joined May 2025 Names Brendan M. Swain (Preferred) , Brendan Swain Emails ****@gmail.com (Confirmed) , ****@shiftbioscience.com (Confirmed) Personal Links Google Scholar ORCID Career & Education History Principal Researcher Shift Bioscience (shiftbioscience.com) 2021 – Present PhD student Department of Pharmacology , University of Cambridge (cam.ac.uk) 2016 – 2020 Advisors, Relations & Conflicts Coauthor Rihab Gam 2024 – 2025 Coauthor Katsiaryna
Brendan Swain - Shift Bioscience Skip to main content Search Close Search Menu Home Platform. Overview. Approach. Platform. Product. Overview. SB101. SB000. Company. Overview. Leadership. Advisors. Investors. News. Contact. x-twitter linkedin Brendan Swain Ph.D CSO & Founder Leadership. Brendan is a co-founder of Shift and since 2021 has led the company’s scientific program as Chief Scientific Officer. Brendan pioneered the first accurate single cell aging clock, and at Shift, developed single-cell aging clock models for human cells that were crucial in establishing the Company’s target id